Emmanuel Scalais

Dr. Emmanuel Scalais


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Pediatric Neurology
Verified
Journal Article
Closed access
ESEmmanuel Scalais
Emmanuel Scalais
EOElise Osterheld
Elise Osterheld
CWChristiane Weitzel
Christiane Weitzel
LMLinda De Meirleir
Linda De Meirleir
FMFrederic Mataigne
Frederic Mataigne
JHJohan L.K. Van Hove
Johan L.K. Van Hove

1 July 2019 in JIMD Reports
Verified
Journal Article
Open access
PDF file
ESEmmanuel Scalais
Emmanuel Scalais
EOElise Osterheld
Elise Osterheld
CGChristine Geron
Christine Geron
CPCharlotte Pierron
Charlotte Pierron
RCRonit Chafai
Ronit Chafai
LMLinda De Meirleir
Linda De Meirleir
Intracellular cobalamin metabolism (ICM) defects can be present as autosomal recessive or X‐linked disorders. Parenteral hydroxocobalamin (P‐OHCbl) is the mainstay of therapy, but the optimal dose has not been determined. Despite early treatment, long‐term complications may develop. We have analyzed the biochemical and clinical responses in five patients with early onset of different types of ICM defects (cblC: patients 1‐3; cblA: patient 4; cblX: patient 5) following daily P‐OHCbl dose intensification (DI). In patient 4, P‐OHCbl was started at age 10 years and in patient 5 at age 5 years. OHCbl was formulated at either, 5, 25, or 50 mg/mL. P‐OHCbl was intravenously or subcutaneously (SQ) delivered, subsequently by placement of a SQ injection port except in patient 4. In all patients, homocysteine and methylmalonic acid levels, demonstrated an excellent response to various P‐OHCbl doses. After age 36 months, patients 1‐3 had a close to normal neurological examination with lower range developmental quotient. In patient 3, moderate visual impairment was present. Patient 4, at age 10 years, had normal renal, visual and cognitive function. In cblX patient 5, epilepsy was better controlled. In conclusion, P‐OHCbl‐DI caused an excellent control of metabolites in all patients. In the three cblC patients, comparison with patients, usually harboring identical genotype and similar metabolic profile, was suggestive of a positive effect, in favor of clinical efficacy. With P‐OHCbl‐DI, CblA patient has been placed into a lower risk to develop renal and optic impairment. In cblX patient, lower P‐OHCbl doses were administrated to improve tolerability.

22 October 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
ESEmmanuel Scalais
Emmanuel Scalais
JBJean Bottu
Jean Bottu
RWRonald J. A. Wanders
Ronald J. A. Wanders
SFSacha Ferdinandusse
Sacha Ferdinandusse
HWHans R. Waterham
Hans R. Waterham
LMLinda De Meirleir
Linda De Meirleir

11 August 2023 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
ESEmmanuel Scalais
Emmanuel Scalais
CGChristine Geron
Christine Geron
CPCharlotte Pierron
Charlotte Pierron
SCSandra Cardillo
Sandra Cardillo
VSVincent Schlesser
Vincent Schlesser
LRLuc Regal
Luc Regal

29 April 2016 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
ESEmmanuel Scalais
Emmanuel Scalais
ACAnne‐Catherine Connerotte
Anne‐Catherine Connerotte
KDKarine Despontin
Karine Despontin
ABArmand Biver
Armand Biver
CGChantal Ceuterick‐De Groote
Chantal Ceuterick‐De Groote
LMLinda De Meirleir
Linda De Meirleir